Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $22.6 million, representing a 53% increase compared to the prior year period [18] - Gross margin reached 50.6%, up 11 points year over year, marking the first time it exceeded 50% in the company's history [9][19] - The company expects continued gross margin expansion, aiming for 70%+ margins in the coming years [9][19] Business Line Data and Key Metrics Changes - Approximately 4,700 prescriptions were written for the ASSURE system in Q2 2026, contributing to the revenue growth [8] - Revenue growth was driven by a 54% year-over-year increase in prescriptions, reflecting market share gains and activation of new accounts [18] Market Data and Key Metrics Changes - The wearable cardioverter defibrillator (WCD) market is estimated to be growing in the low double digits, with only 14% of the eligible U.S. addressable market currently utilizing WCD therapy [10][14] - The ACE-PAS study, the largest real-world prospective WCD study, enrolled over 21,000 patients and demonstrated the ASSURE system's effectiveness [10][11] Company Strategy and Development Direction - The company is focused on expanding its sales organization to penetrate existing accounts and attract new ASSURE prescribers [14] - The strategy includes enhancing revenue cycle management capabilities and increasing the in-network patient mix, which has improved from approximately 70% to the low 80s [15][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong revenue growth and gross margin expansion as key indicators of success [17] - The company is optimistic about the impact of recent clinical data on market expansion and prescription guidelines [10][46] Other Important Information - GAAP operating expenses for Q2 were $43.2 million, reflecting investments in commercial expansion and public company costs [21] - The company has increased its fiscal year 2026 revenue guidance to $91 million, representing a growth of 52% compared to fiscal year 2025 [22] Q&A Session Summary Question: Guidance for the year and Q3 seasonality - Management indicated that revenue growth is driven by prescription volume and in-network mix, with a focus on consistent quarterly results to build investor trust [26][28] Question: Use of proceeds from the recent equity offering - The company plans to use the additional capital to strengthen its balance sheet and support key growth drivers [30] Question: Impact of AHA data on market share and growth - Management noted that while it is early to see numerical impacts, anecdotal evidence suggests clinicians are reassessing their decisions based on new data [36][38] Question: Rep productivity and sales force hiring plans - The company is on track to double its sales force from 70 to approximately 140 reps over the next few years [40] Question: Timing for potential guideline changes - Management clarified that while growth does not rely on guideline changes, they believe the clinical evidence warrants a review [46][47] Question: Prescription volume sustainability - Management expects the strong prescription growth to continue, supported by ongoing penetration of existing accounts and the addition of new hospitals [63] Question: OpEx spending plans - The company is committed to investing in team expansion and revenue cycle management capabilities to support growth [67][69] Question: Clinical specialist role impact - The strategy of hiring clinical specialists to support high-performing accounts has received positive feedback and is seen as beneficial for account management [73][74] Question: Path to achieving 70% gross margins - Management is confident in achieving sustained gross margin expansion through volume leverage and improved in-network mix [78]